Our primary aim is to identify subgroups of rNB patients who have potentially targetable genetic (ALK, MAPK pathway, Metabolic - related genes) and / or immunologic (tumor -
associated macrophage infiltration and / or programmed death ligand [PD - L1] expression) biomarkers in rNB.